🧫
NPM1 knockout tumor progression study in syngeneic mice
active
experiment
Created: 2026-04-10T14:35:17
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-4e7dc743-7b25-454d-9ab5-ee8a098a12ee
🧫 Experiment Protocol
ValidationcancerNPM1syngeneic mice with subcutaneous tumor xenograftsproposed
Subcutaneous inoculation of Npm1-deficient tumor cells into syngeneic mice to examine the roles of NPM1 in tumor progression and tumor microenvironment reprogramming. The study evaluated tumor growth kinetics, survival of tumor-bearing mice, immune cell infiltration patterns, and activation states using comprehensive flow cytometry, CyTOF, immunohistochemistry staining, and RNA-seq analysis. Loss of NPM1 was shown to inhibit tumor progression and enhance survival, with increased CD8+ T cell infiltration and activation alongside reduced presence of immunosuppressive cells.
PRIMARY OUTCOME
tumor progression and survival rates
EXPECTED OUTCOMES
NPM1 deficiency would affect tumor progression and immune microenvironment
SUCCESS CRITERIA
Significant changes in tumor growth, survival, and immune cell populations
PROTOCOL
Subcutaneous inoculation of Npm1-deficient tumor cells followed by monitoring tumor growth, survival analysis, and comprehensive immune profiling using CyTOF, flow cytometry, immunohistochemistry, and RNA-seq
LINKED HYPOTHESES
Source: PMID 39402629 ↗
🧫 Experiment Extras
PATHWAY
antigen presentation pathway, MHC-I and MHC-II presentation
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.